Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Microvessel Imaging for Characterization of Chronic Kidney Disease
NCT05764642Phase 2Enrolling by invitation
- Sponsor
- Mayo Clinic
- Start
- Aug 2023
- Primary completion
- Apr 2028
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of perflutren lipid microspheres in chronic kidney disease (CKD) (2 arms), sponsored by Mayo Clinic. Primary endpoints: Renal cortex microvessel density, Renal cortex microvessel diameter and 1 more. Started Aug 2023; status: enrolling by invitation.
02
Drugs
perflutren lipid microspheres
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05764642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05764642.